Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination

International Journal of Cancer

Volumn 121, Issue 9, 2007, Pages 2042-2048

  Karbach, Julia ^a   Gnjatic, Sacha ^b   Pauligk, Claudia ^a   Bender, Armin ^a   Maeurer, Markus ^c   Schultze, Joachim L ^d   Nadler, Kerstin ^a   Wahle, Claudia ^a   Knuth, Alexander ^e   Old, Lloyd J ^b   Jäger, Elke ^a  

^a KRANKENHAUS NORDWEST   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cytotoxic T cells; Peptide vaccination; Tumor cell recognition; Tumor immunity

Indexed keywords

CPG 7909; HLA A2 ANTIGEN; NY ESO 1 ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CASE REPORT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MIXED LYMPHOCYTE CULTURE; PATIENT MONITORING; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION;

EID: 34648836563     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22957     Document Type: Article

References (28)

1. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stocken E, Old LJ, Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-70.
2. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001;92:856-60.
3. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
4. Jager E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jager D, Arand M, Ritter G, Old LJ, Knuth A. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 1999;84:506-10.
5. + T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004;172:3289-96.
6. + T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 2003;100:8862-7.
7. Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jager D, Arand M, Ritter G, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000;97:4760-5.
8. Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer 1999;82:442-8.
9. Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derre L, Diez E, Dreno B, Jotereau F, Labarriere N. Identification of five new HLA-B*3501- restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol 2003;171:6283-9.
10. Chen JL, Dunbar PR, Gileadi U, Jager E, Gnjatic S, Nagata Y, Stocken E, Panicali DL, Chen YT, Knuth A, Old LJ, Cerundolo V. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 2000;165:948-55.
11. Gnjatic S, Nagata Y, Jager E, Stocken E, Shankara S, Roberts BL, Mazzara GP, Lee SY, Dunbar PR, Dupont B, Cerundolo V, Ritter G, et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci USA 2000;97:10917-22.
12. + T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 2000;191:625-30.
13. + T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 2000;165:1153-9.
14. Biskamp M, Jäger E, Karbach J, Neumann A, Jäger D, Gnjatic S, Pugliese E, Hoffman E, Old LJ, Knuth A. Phase I study of intensive course immunization with NY-ESO-1 peptides in HLA-A2+ patients with NY-ESO-1+ cancer. Proc Am Soc Clin Oncol 2003; p 176 (abstract 706).
15. + T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000;97:12198-203.
16. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 1992;360:258-61.
17. Jager E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager D, Ilsemann C, Hagedorn M, Oesch F, Knuth A. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996;67:54-62.
18. + T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci USA 2002;99:11813-8.
19. + T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 2002;110:1813-22.
20. + T lymphocytes involving loss of tetramer labeling. Eur J Immunol 2002;32:1688-97.
21. McKee MD, Roszkowski JJ, Nishimura MI. T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med 2005;3:35.
22. Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M, Weber JS, Lee PP. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med 2004;1:e28.
23. Snyder JE, Bowers WJ, Livingstone AM, Lee FE, Federoff HJ, Mosmann TR. Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing. Nat Med 2003;9:231-5.
24. + T-cell responses to the tumor-specific antigen NY-ESO-1. J Immunother 2005;28: 252-7.
25. Trautmann L, Rimbert M, Echasserieau K, Saulquin X, Neveu B, Dechanet J, Cerundolo V, Bonneville M. Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses. J Immunol 2005;175:6123-32.
26. + T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 2000;60:4499-506.
27. Michielin O, Blanchet JS, Fagerberg T, Valmori D, Rubio-Godoy V, Speiser D, Ayyoub M, Alves P, Luescher I, Gairin JE, Cerottini JC, Romero P. Tinkering with nature: the tale of optimizing peptide based cancer vaccines. Cancer Treat Res 2005;123:267-91.
28. + T-cells by flow cytometry. J Immunol Methods 2006;311:31-46.